The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome

Histopathology

Volumn 46, Issue 3, 2005, Pages 270-279

  Feakins, R M ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Bcl 2; Gastrointestinal stromal tumour; p53; Prognosis

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL NUCLEUS; CELL SHAPE; COLON TUMOR; DISEASE COURSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM TUMOR; SMALL INTESTINE TUMOR; STOMACH TUMOR;

COLON; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINE, SMALL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECTUM; SEVERITY OF ILLNESS INDEX; STOMACH; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14844314779     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02071.x     Document Type: Article

References (37)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum. Pathol. 1999; 30; 1213-1220.
2. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999; 34; 416-424.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. Int. J. Pathol. 2001; 438; 1-12.
4. Berman J, O'Leary TJ. Gastrointestinal stromal tumors: answers and questions. Hum. Pathol. 2002; 33; 456-458.
5. Carrillo R, Candia A, Rodriguez-Peralto JL et al. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum. Pathol. 1997; 28; 160-165.
6. Emory TS, Sobin LH, Lukes L et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am. J. Surg. Pathol. 1999; 23; 82-87.
7. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56; 2242-2250.
8. Lewin KJ, Riddell RH, Weinstein WM. Mesenchymal tumors. In Lewin KJ, Riddell RH. Weinstein WM eds. Gastrointestinal pathology and its clinical implications. New York. NY: Igaku-Shoin. 1992: 284-341.
9. Suster S. Gastrointestinal stromal tumors. Semin. Diagn. Pathol. 1996; 13; 297-313.
10. Cooper PN, Quirke P, Hardy GJ et al. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract. Am. J. Surg. Pathol. 1992; 16; 163-170.
11. Fletcher CDM, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33; 459-465.
12. Tworek JA, Goldblum JR, Weiss SW et al. Stromal tumors of the anorectum. A clinicopathologic study of 22 cases. Am. J. Surg. Pathol. 1999; 23; 946-954.
13. Miettinen M, Sarlomo-Rikala M, Kovatich AJ. Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours. Virchows Arch. Int. J. Pathol. 1998; 433; 255-260.
14. El-Naggar AK, Ro JY, McLemore D et al. Gastrointestinal stromal tumors: DNA flow-cytometric study of 58 patients with at least five years of follow-up. Mod. Pathol. 1989; 2; 511-515.
15. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999; 59; 4297-4300.
16. Baas IO, Mulder J-WR, Offerhaus GJA et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 1994; 172; 5-12.
17. Hollstein M, Sidrensky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991; 253; 49-53.
18. Hall PA, Meek D, Lane DP. p53-integrating the complexity (editorial). J. Pathol. 1996; 180; 1-5.
19. Hockenbery D, Nunez G, Milliman C et al. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348; 334-336.
20. Cleary ML, Sklar J. Nucleotide sequence of a t(14:18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl Acad. Sci. USA 1985; 82; 7439-7443.
21. Nakanishi H, Ohsawa M, Naka N et al. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 1997; 54; 238-244.
22. Leahy DT, Mulcahy HE, O'Donoghue DP et al. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 1999; 35; 360-367.
23. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J. Pathol. 1995; 177; 221-224.
24. Al-Bozom IA. p53 expression in gastrointestinal stromal tumors. Pathol. Int. 2001; 51; 519-523.
25. Cai J, Jiang Y, Zhang Y et al. Quantitation of p53 protein expression in gastrointestinal smooth muscle tumors. Clinicopathological correlation and prognostic significance. Chin. Med. J. 1995; 108; 669-673.
26. Lopes JM, Silva P, Seixas M et al. Microsatellite instability is not associated with degree of malignancy and p53 expression of gastrointestinal stromal tumours. Histopathology 1998; 33; 579-581.
27. Cunningham RE, Abbondanzo SL, Chu WS, Emory TS, Sobin LH, O'Leary TJ. Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl. Immunohistochem. Mol. Morph. 2001; 9; 19-23.
28. Panizo-Santos A, Sola I, Vega F et al. Predicting metastatic risk of gastrointestinal stromal tumors. Role of cell proliferation and cell cycle regulatory proteins. Int. J. Surg. Pathol. 2000; 8; 133-144.
29. Wong NA, Young R, Malcomson RD et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003; 43; 118-126.
30. Chilosi M, Facchettti F, Dei Tos AP et al. bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J. Pathol. 1997; 181; 362-367.
31. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am. J. Surg. Pathol. 1998; 22; 863-872.
32. Feakins RM, Mulcahy HE, Nickols CD et al. p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome. Histopathology 1999; 35; 162-169.
33. Hirakawa N, Naka T, Yamamoto I et al. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum. Pathol. 1996; 27; 1060-1065.
34. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61; 759-767.
35. Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000; 156; 791-795.
36. Kawai A, Noguchi M, Beppu Y et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 1994; 73; 2499-2505.
37. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344; 1052-1056.